臨床研究等提出・公開システム

Effectiveness of Tezepelumab on Asthma control and Cough: A prospective, multi-center, observational study (Tezepelumab PRO study)

Effectiveness of Tezepelumab on Asthma control and Cough: A prospective, multi-center, observational study (Tezepelumab PRO study)

Kawano Yoshiaki

AstraZeneca K.K.

Grand Front Osaka Tower B, 3-1 Ofuka-cho, Kita-ku, Osaka City, Osaka

Yoshiaki.Kawano@astrazeneca.com

Uchimura Hitomi

AstraZeneca K.K.

Grand Front Osaka Tower B, 3-1 Ofuka-cho, Kita-ku, Osaka City, Osaka

+81-6-4802-3600

Hitomi.Uchimura@astrazeneca.com

Not Recruiting

Aug. 05, 2023

Observational

1. Patients aged >=18 years who provide informed consent and who receive new prescription of Tezepelumab as per the physician's decision at baseline according to the package insert saying "Tezepelumab is given to patient with asthma (limited to severe or refractory patient whose asthma symptoms cannot be controlled even with existing treatment)"
2. ACQ-6 >=1.5 at baseline
3. Patients with persistent cough >=8 weeks up until the baseline visit according to The Japanese Respiratory Society Guidelines for the Management of Cough and Sputum 2019

1. Patients who had asthma exacerbation within one month before study enrollment
2. Patients who had the biologics treatment in following period prior to the enrollment
-omalizumab in 2 or 4 weeks depending on the body weight and total IgE amount
-mepolizumab in 4 weeks
-Benralizumab in 8 weeks
-Dupilumab in 2 weeks
3. Patients with cough related diseases other than asthma as determined by treating physicians
4. Patients participating in studies that affect this study (study with other interventional treatment to evaluate efficacy/safety of treatment in patients with cough, asthma, or allergic/eosinophilic diseases)
5. Any disorder, including heart failure, malignancy, morbid obesity(BMI>=35) , respiratory infectious disease that is not stable (e.g. patients who need medical treatment) in the opinion of the investigator and could:
- Affect the safety of the patient throughout the study
- Impede the patient's ability to complete the entire duration of study
6. Patients with pregnancy or lactation period

Both

asthma

Mean change in ACQ-6 at week 52 from baseline

Key secondary Outcome measure:
Mean change in LCQ at week 52 from baseline
Secondary Outcome measure:
1. Mean change in LCQ at week 4,12,24 from baseline
2. Mean change in ACQ-6 at week 4,12,24 from baseline
3. Asthma exacerbation rate during 52 weeks before/after Tezepelumab initiation
Ratio of annual asthma exacerbation rate between previous 52 weeks and Tezepelumab treated 52 weeks

+81-3-6416-1868

Aug. 03, 2023

No

none